« Back
Home /
Partner: Protein Alternatives |Hölzel Diagnostika

Protein Alternatives

Protein Alternatives is a young emerging biotechnology company based in Madrid, Spain. The main focus of the company is cancer detection through design and development of biomarker-based assays and targeted therapy with monoclonal antibodies. Protein Alternatives was founded in 2006 and soon expanded with numerous research and development laboratories.

The company’s main aim is clinical disease management and the development of biomarker-based assays for cancer screening. This includes all phases of the biomarker assay chain, including the identification and validation of markers, assay development and clinical validation, as well as regulatory approval (CE marking). ProAlt provides high quality reagents specifically for genomic and proteomic use. This also includes immunohistochemistry of tissues. Original and “rare” proteins are being investigated for their possible use as biomarkers for cancer.

Protein Alternatives offers synthesized proteins and antibodies, as well as various tailor-made designs and protein and antibody variants. Services include protein expression, antibody synthesis and recombinant antibody production. Three different but complementary expression systems: E. coli (bacterial system), baculovirus in insect cells and mammalian cells are offered to meet the specific research questions.

The COLODETECT® test is used for the early detection of colorectal cancer in people with medium and high risk of disease, men and women aged 50-75 years. A non-invasive blood analysis is able to detect autoantibodies associated with the disease. When a tumor is present, abnormal proteins are formed, which are referred to as tumor-associated antigens (TAA) or neoantigens. The patient's immune response consists of specially formed antibodies that can easily be detected in the blood. The decisive advantage is the early diagnosis even before symptoms appear or before other biomarkers can be measured. Another feature of autoantibodies that make them suitable for use as biomarkers are their high relative concentrations, their extended long half-life and their good stability in the blood. The test convinces with ease of use, recognition accuracy and affordable costs.

The innovative company ProAlt furthermore focuses on researching current targets (such as CDH17 and IL13Ra2) for promising treatment of advanced metastatic diseases. The treatment of colon, melanoma or breast cancer can be improved with the products by Protein Alternatives.

Protein Alternatives SL's product portfolio includes recombinant proteins, polyclonal antibodies, diagnostic kits and monoclonal antibodies.